Lv3
298 积分 2022-09-04 加入
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
9小时前
已完结
Cadonilimab (a PD-1/CTLA-4 Bispecific Antibody) plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase II Clinical Trial
10小时前
已完结
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
10小时前
已完结
Discovery of Selective and Potent Macrocyclic CDK9 Inhibitors for the Treatment of Osimertinib-Resistant Non-Small-Cell Lung Cancer
7个月前
已完结
Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization
8个月前
已完结
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
8个月前
已完结
Fenobody: A Ferritin-Displayed Nanobody with High Apparent Affinity and Half-Life Extension
8个月前
已完结
Albumin-binding domain from Streptococcus zooepidemicus protein Zag as a novel strategy to improve the half-life of therapeutic proteins
8个月前
已完结
Reduced elimination of IgG antibodies by engineering the variable region
8个月前
已完结
ELPylated anti‐human TNF therapeutic single‐domain antibodies for prevention of lethal septic shock
8个月前
已完结
皖公网安备34019202002308
